For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Research and development | 27,960 | 22,710* | 22,178 | 22,882 |
| General and administrative | 6,906 | 5,303* | 5,728 | 5,731 |
| Total operating expenses | 34,866 | 28,012 | 27,906 | 28,613 |
| Total operating loss | -34,866 | -28,012* | -27,906 | -28,613 |
| Interest income, including amortization and accretion income | 1,190 | 1,392* | 1,815 | 1,678 |
| Other income (expense) | 2 | 151* | -13 | -36 |
| Total other income | 1,192 | 1,542* | 1,802 | 1,642 |
| Loss before income taxes | -33,674 | -26,470* | -26,104 | -26,971 |
| Income tax provision, net | 11 | -3* | 26 | 48 |
| Net loss | -33,685 | -26,467* | -26,130 | -27,019 |
| Unrealized loss on marketable securities | -78 | -132* | 57 | -88 |
| Currency translation adjustment | -27 | -178* | -13 | 8 |
| Total other comprehensive loss | -105 | -311* | 44 | -80 |
| Total comprehensive loss | -33,790 | -26,778 | -26,086 | -27,099 |
| Basic EPS | -0.5 | -0.469 | -0.4 | -0.47 |
| Diluted EPS | -0.5 | -0.469 | -0.4 | -0.47 |
| Basic Average Shares | 67,447,576 | 57,060,434 | 65,936,672 | 58,015,718 |
| Diluted Average Shares | 67,447,576 | 57,060,434 | 65,936,672 | 58,015,718 |
Aura Biosciences, Inc. (AURA)
Aura Biosciences, Inc. (AURA)